Patent: 7,452,684
✉ Email this page to a colleague
Summary for Patent: 7,452,684
Title: | Collagen XXII, a novel human collagen and uses thereof |
Abstract: | The invention provides isolated nucleic acids molecules, designated collagen XXII nucleic acid molecules, which encode a novel collagen. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing collagen XXII nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a collagen XXII gene has been introduced or disrupted. The invention still further provides isolated collagen XXII proteins, fusion proteins, antigenic-peptides and anti-collagen XXII antibodies. Diagnostic methods utilizing compositions of the invention are also provided. |
Inventor(s): | Burgeson; Robert Eugene (Palm Springs, CA), Koch; Manuel (Cambridge, MA), Keene; Douglas R. (Portland, OR), Brunken; William Joseph (Canton, MA), Bruckner-Tuderman; Leena (Munster, DE) |
Assignee: | The General Hospital Corporation (Boston, MA) |
Application Number: | 11/584,250 |
Patent Claims: | see list of patent claims |
Details for Patent 7,452,684
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Smith & Nephew, Inc. | SANTYL | collagenase | Ointment | 101995 | 06/04/1965 | ⤷ Try a Trial | 2021-07-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |